ইউরোপীয় ইউনিয়ন - লিথুয়েনীয় - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - hemoraginės karštligės, ebola - vakcinos - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

লিত্ভা - লিথুয়েনীয় - SMCA (Valstybinė vaistų kontrolės tarnyba)

uab „arli baltic“, Šaltinių g. 26-30, lt-03233 vilnius. - etanolis, etilo alkoholis - veikliosios medžiagos cas nr.: 64-17-5, eb nr.: 200-578-6, veikliosios medžiagos pavadinimas: etanolis, etilo alkoholis, koncentracija: 80% , veiklioji - asmens higiena

লিত্ভা - লিথুয়েনীয় - SMCA (Valstybinė vaistų kontrolės tarnyba)

uab "arli baltic”, Šaltinių g. 26-30, lt-03233 vilnius. - didecildimetilamonio chloridas; didecildimetilamonio chloridas - veikliosios medžiagos cas nr.: 7173-51-5, eb nr.: 230-525-2, veikliosios medžiagos pavadinimas: didecildimetilamonio chloridas, koncentracija: 4% , veiklioji; veikliosios medžiagos cas nr.: 7173-51-5, eb nr.: 230-525-2, veikliosios medžiagos pavadinimas: didecildimetilamonio chloridas, koncentracija: 4% , veiklioji - maisto ir pašarų sritis

লিত্ভা - লিথুয়েনীয় - SMCA (Valstybinė vaistų kontrolės tarnyba)

uab "arli baltic”, Šaltinių g. 26-30, lt-03233 vilnius. - didecildimetilamonio chloridas; didecildimetilamonio chloridas - veikliosios medžiagos cas nr.: 7173-51-5, eb nr.: 230-525-2, veikliosios medžiagos pavadinimas: didecildimetilamonio chloridas, koncentracija: 0.05% , veiklioji; veikliosios medžiagos cas nr.: 7173-51-5, eb nr.: 230-525-2, veikliosios medžiagos pavadinimas: didecildimetilamonio chloridas, koncentracija: 0.05% , veiklioji - maisto ir pašarų sritis

ইউরোপীয় ইউনিয়ন - লিথুয়েনীয় - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcinos - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. naudoti šios vakcinos turėtų būti laikantis oficialių rekomendacijų.

ইউরোপীয় ইউনিয়ন - লিথুয়েনীয় - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcinos - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

ইউরোপীয় ইউনিয়ন - লিথুয়েনীয় - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vakcinos - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. naudoti šios vakcinos turėtų būti laikantis oficialių rekomendacijų.

ইউরোপীয় ইউনিয়ন - লিথুয়েনীয় - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vakcinos - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. naudoti šios vakcinos turėtų būti laikantis oficialių rekomendacijų.

ইউরোপীয় ইউনিয়ন - লিথুয়েনীয় - EMA (European Medicines Agency)

novartis ireland ltd - ofatumumab - išsėtinė sklerozė, grįžtamoji-pervedimo - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.

ইউরোপীয় ইউনিয়ন - লিথুয়েনীয় - EMA (European Medicines Agency)

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. naudoti šios vakcinos turėtų būti laikantis oficialių rekomendacijų. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. naudoti šios vakcinos turėtų būti laikantis oficialių rekomendacijų.